Sana Biotechnology, Inc. (NASDAQ:SANA) ranks among the best CRISPR stocks to buy. On June 24, Citizens JMP reaffirmed its $5 ...

For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss and T2D remission, according to a study presented ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal ...

Abbott and Dexcom launched the first over-the-counter CGMs last year. Dexcom’s Stelo was geared toward people with Type 2 diabetes who don’t take insulin, although it could also be used by people who ...

China, 24/06/2025 (informazione.it - comunicati stampa - scienza e tecnologia) "These Phase 2 data highlight the significant, best-in-class potential of BGM0504 as a treatment for type 2 diabetes ...

SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the ...

New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease iRhythm - GlobeNewswire - 1 hour ago ...

Incidence of Cardiac Arrhythmias in Patients with Diabetes: A Real-World Study Type 2 Diabetes (T2D) contributes to development of arrhythmias through autonomic dysfunction, electrical remodeling ...

Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the ...

ADA Scientific Sessions: Diabetes and peripheral artery disease-evolving role of GLP-1 RA and new insights from the STRIDE trial - Saturday 21 June; 13:30-15:00 CDT ...

Retrospective real-world analyses of patients with type 2 diabetes—some of whom also had chronic kidney disease—demonstrate cardiac arrhythmias present frequent and early, often preceding ...